Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. - Wikidata - awgldk - TriplyDB

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

http://www.wikidata.org/entity/Q45974600

about

Influenza and the use of oseltamivir in children What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia?Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study The pharmacological management of severe influenza infection - 'existing and emerging therapies'.Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic.Respiratory viral infections among hospitalized adults: experience of a single tertiary healthcare hospital.Influenza-associated intensive-care unit admissions and deaths - California, September 29, 2013-January 18, 2014.An overview of the characteristics of the novel avian influenza A H7N9 virus in humans.Neuraminidase inhibitor therapy in a military population.Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations.Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015 Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.Antivirals in seasonal and pandemic influenza--future perspectives.Advances in antivirals for non-influenza respiratory virus infections.Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head Geldanamycin Reduces Acute Respiratory Distress Syndrome and Promotes the Survival of Mice Infected with the Highly Virulent H5N1 Influenza Virus.Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients.Influenza SIRS with Minimal Pneumonitis.Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors.Comparative Epidemiology of Human Fatal Infections with Novel, High (H5N6 and H5N1) and Low (H7N9 and H9N2) Pathogenicity Avian Influenza A Viruses.Optimizing antiviral therapy for influenza: understanding the evidence.Peramivir: an intravenous neuraminidase inhibitor.Comparison of High-Dose Versus Standard Dose Oseltamivir in Critically Ill Patients With Influenza.Impact of HIV on the severity of influenza.Maoto, a Traditional Japanese Herbal Medicine, Inhibits Uncoating of Influenza Virus.The Impact of Obesity and Timely Antiviral Administration on Severe Influenza Outcomes Among Hospitalized Adults.Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients.Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.Impact of Prompt Influenza Antiviral Treatment on Extended Care Needs After Influenza Hospitalization Among Community-Dwelling Older Adults.Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015.The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management.

P2860

Q26739661-8EE16973-20D2-4C00-8961-F797AF19DB89 Q26852219-74001346-E356-43B2-B67F-479262C3E538 Q28537982-B35984F5-F419-4072-B87F-CEA0E6737DC1 Q30243907-FD8A7E2E-3936-49D4-96F2-CAC36E939413 Q30352949-CD6E662D-56BC-46D5-B599-911B363A423A Q30353217-F72D32A8-8DA3-4F4D-B6A3-3491B7C448E7 Q30357688-C6BD19D5-E0FF-457B-9ADD-C997316B1FB7 Q30358632-5B326F66-2973-4AA9-8794-4A66A49F6009 Q30359271-1A7A3A16-BC52-498E-83CE-5BCA9DECD7F9 Q30372931-5FD3A4B3-28FC-420B-928E-8C65B1417891 Q30374549-05B84F49-7E3B-4218-97F9-EEAB5AA20A25 Q30375212-84698E11-7086-46A3-A6B2-5DCEBEB68DF8 Q30381799-07D3128D-DE37-4287-8463-E2A13817A45B Q30390145-EA836F0D-6792-4D09-AFFA-2BD4841E7B3E Q30392472-A4DBEC3C-B98F-4A76-8EC5-B1F6BE0D2664 Q30396792-FFE442E7-0332-4254-86C3-EFEB6F24DB2D Q30398670-FAEDA2D5-B196-47AC-9F64-5A1183ABE125 Q30425358-2BB39D85-0309-46D3-9E6A-6CD14C5C8023 Q30457132-A2F068B7-DCAE-40B5-A197-A8768FDBF242 Q31155532-D64DBD05-0750-4060-9797-A920A01A3E19 Q33743865-1C3B808A-5240-461C-8F75-9812C5332F4D Q33799835-A4547F67-840F-4BC5-B716-3F0F693A89F7 Q33838098-40C88EB1-95DF-44C6-BA0D-3BCFFE49F6EE Q35076802-EC6290DD-0B41-47AC-80B2-8E80B9BD8A3F Q36376234-BD501FA4-4D1B-4967-89DA-B0E776C9B75E Q37218517-77E51DEB-B24D-4EAA-9149-9AD90DDC8119 Q37374096-C9621733-93B7-46FD-B340-AA7C0CBFF3A3 Q37724526-38517DFB-A26C-4165-82B2-91850A4D9513 Q38361244-699F451C-0AC8-46BB-9CA0-C15127D1A250 Q38543777-8A0ED04F-674A-49F5-AAF9-30CB1EFB724F Q39907415-F75FC91E-CCB7-49B7-9B65-C7DA12432910 Q39966481-62829AF6-2274-4AD8-938F-01FE89B3DA85 Q40042197-63A258D6-A3CF-486A-BA51-31D0E8A509A4 Q40047799-DBF7BAD4-06EF-4CA6-9282-92BC5EB9D5C7 Q40680147-77107C55-5B0C-4B63-86C8-8D283E3877AA Q40748977-ADAC0DB3-BC25-4E7E-AA45-728FF437B222 Q41019102-839A96A5-BF42-421A-B82F-EB251466F719 Q41395483-3EA6AF46-6567-4FD4-A938-21904AC55F00 Q41589233-8F777B67-7896-4C34-BA25-A8F9F67F540D Q41927260-BD42D267-E335-46CD-9CC5-855CAD8046A9

P2860

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

http://www.wikidata.org/entity/Q45974600

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Treatment with neuraminidase i ...... with influenza A (H1N1)pdm09.

@en

Treatment with neuraminidase inhibitors for critically ill patients with influenza A

@nl

type

label

Treatment with neuraminidase i ...... with influenza A (H1N1)pdm09.

@en

Treatment with neuraminidase inhibitors for critically ill patients with influenza A

@nl

prefLabel

Treatment with neuraminidase i ...... with influenza A (H1N1)pdm09.

@en

Treatment with neuraminidase inhibitors for critically ill patients with influenza A

@nl

P1433

Q45974600-FB836056-4447-4F78-8C2E-4F6F0CE28402

P1476

Q45974600-71417ED2-EA72-41EE-AB3D-F87B9C3F6401

P2093

Q45974600-35CAC3F6-26CF-486D-A47F-67CEE788B142

Q45974600-408CEE4E-FE86-4BED-94EC-407336313E0C

Q45974600-A224821C-3C2F-4BBC-89BA-C546BE610CB7

Q45974600-B407E0B7-4DD5-4312-A363-724A1374D4B7

Q45974600-BEBBD3AE-73ED-4228-AEB7-2573A958806E

Q45974600-DCC3829D-EAC6-4D6A-8774-0013335FAE86

Q45974600-F90CDFB8-27AA-4507-8497-6A718218C24F

P2860

Q45974600-0D881FC4-53CF-4C99-9CBE-424BE14B484E

Q45974600-13267CE3-E2FE-4251-AF9D-50ECA5002119

Q45974600-1A712C54-8295-4AF3-8422-DC947B29CC8A

Q45974600-3AE4E8F8-202E-4E7C-BCB6-C0A1F157F909

Q45974600-3E473A53-6C28-4AC9-BB40-300B0BE4C426

Q45974600-401BB57A-4450-463C-801F-D97EB464C9A0

Q45974600-40ECC068-8A00-4C30-A11F-E1A820F566D8

Q45974600-508E6D22-D462-479A-A407-5929FC07FE43

Q45974600-553B9587-CD22-427B-AE21-55F6EE5A72B7

Q45974600-6AA5B7E2-F9B6-461D-BF64-701CAED4A46A

P304

Q45974600-C7488032-2D34-4435-AA11-9E5ED9C6DF79

P31

Q45974600-0EF3E90A-E35F-4DA7-8CA7-74732F332A0A

P356

Q45974600-6647338C-9D44-4B37-BA20-BE7B3CA0DA9A

P407

Q45974600-17919F54-C546-47A0-86EE-E6D0368D0410

P433

Q45974600-B73F2DB4-41A9-4CE0-81A1-741689D71BDC

P478

Q45974600-35C1D530-DD19-41DB-BE6E-3C0F27BB87DA

P50

Q45974600-3D412983-69AC-47E8-88C6-42F0E8DF5675

P577

Q45974600-3773836C-310C-4596-AA69-D2273103FAD9

P5875

Q45974600-C67BD24A-09B3-4CBB-9B81-B551DD409AD1

P698

Q45974600-2C774C8A-95F7-4F53-A7FD-3673A0C7BC05

P921

Q45974600-8E0CAF81-4199-43EA-A8B5-D27374EF708C

P356

P1433

Clinical Infectious Diseases

P1476

Treatment with neuraminidase i ...... with influenza A (H1N1)pdm09.

@en

P2093

Cynthia Yen

http://www.w3.org/2001/XMLSchema#string

Hugo Guevara

http://www.w3.org/2001/XMLSchema#string

Janice K Louie

http://www.w3.org/2001/XMLSchema#string

Meileen Acosta

http://www.w3.org/2001/XMLSchema#string

Michael C Samuel

http://www.w3.org/2001/XMLSchema#string

Robert Schechter

http://www.w3.org/2001/XMLSchema#string

Samuel Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.

Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States.

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection.

Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients.

Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China

Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.

Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.

Duration of viral shedding in hospitalized patients infected with pandemic H1N1

P304

1198-1204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS636

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Timothy M. Uyeki

P577

2012-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230586145

http://www.w3.org/2001/XMLSchema#string

P698

22843781

http://www.w3.org/2001/XMLSchema#string

P921